Author Archives: Thomas Payne

TScan Therapeutics Named Top Place to Work by The Boston Globe for Two Consecutive Years

By

TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

By

TScan Therapeutics Presents Phase 1 Trial Design for Solid Tumor Program at the Society for Immunotherapy of Cancer 38th Annual Meeting

By

TScan Therapeutics Announces Upcoming Presentation at the 65th American Society of Hematology Annual Meeting and Exposition

By

TScan Therapeutics Announces Upcoming Presentations at the 38th Society for Immunotherapy of Cancer Annual Meeting

By

TScan Therapeutics to Participate in Upcoming Investor Conferences

By

TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAME

By

TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

By

TScan Therapeutics Announces Transition of Chief Financial Officer

By

TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-200-A0201 Targeting HPV16 to Treat Solid Tumors

By